McCowage, Geoffrey

Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)

Gajjar, A., Robinson, G. W., Smith, K. S., Lin, T., Merchant, T. E., Chintagumpala, M., Mahajan, A., Su, J., Bouffet, E., Bartels, U., et al. (2021) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentNeuroblastoma Research and Treatments

Cited by 241

Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours

Hsu, K., Middlemiss, S., Saletta, F., Gottschalk, S., McCowage, G. B., & Kramer, B. (2021) · Cancer Gene Therapy

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 51

Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma

Gaspar, N., Hung, G.-Y., Strauss, S. J., Campbell-Hewson, Q., Dela Cruz, F. S., Glade Bender, J. L., Koh, K.-N., Whittle, S. B., Chan, G. C.-F., Gerber, N. U., et al. (2024) · JAMA Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 28

A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma.

Chi, S. N., McCowage, G. B., Hoffman, L., Macy, M., Doleman, S., Blakemore, S. J., Clawson, A., Daigle, S., Tang, J., Roche, M., et al. (2016) · Journal of Clinical Oncology

Chromatin Remodeling and CancerSarcoma Diagnosis and Treatment

Cited by 8